Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 basket trial of Descartes-08 in pediatric patients with select autoimmune diseases, including juvenile dermatomyositis

Next Previous
Trial Profile

Phase 2 basket trial of Descartes-08 in pediatric patients with select autoimmune diseases, including juvenile dermatomyositis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Descartes 08 (Primary)
  • Indications Autoimmune disorders; Dermatomyositis
  • Focus Adverse reactions
  • Acronyms BASKET

Most Recent Events

  • 13 Mar 2025 According to a Cartesian Therapeutics media release, company expect to initiate our Phase 2 pediatric basket trial of Descartes-08 in select autoimmune diseases in the second half of this year.
  • 13 Jan 2025 According to a Cartesian Therapeutics media release, The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis.
  • 13 Jan 2025 According to a Cartesian Therapeutics media release, The Company expects to commence a Phase 2 basket trial of Descartes-08 in pediatric patients with select autoimmune diseases, including juvenile dermatomyositis (JDM), in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top